Dupixent 200 MG/1.14 ML syring 1.14ML
Ended Awarded Last action
- Contract number
- SPE2DR26F7NKF
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,091
Award facts
- Contract value 100% obligated
- $33,090.74 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $33,090.74 delivery order to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 mL syringes on January 6, 2026, with an ultimate completion date of January 7, 2026. This non-set-aside contract is structured as a firm fixed-price delivery order and represents a fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999.9 billion through December 2026). The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and other inflammatory conditions, making this order part of the agency's broader pharmaceutical supply chain supporting military healthcare systems.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (doing business as AmerisourceBergen), is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement. The company's DLA IDC serves as a comprehensive global pharmaceutical support vehicle enabling the delivery of specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains to military treatment facilities and other federal healthcare systems. This delivery order reflects the company's ongoing role in supplying essential pharmaceutical products to support Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DR26F7NKF?
SPE2DR26F7NKF was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26F7NKF worth?
The government has obligated $33,091 on SPE2DR26F7NKF.
Is contract SPE2DR26F7NKF an order under another contract?
Yes. SPE2DR26F7NKF is a delivery order under SPE2DR25D7059, an indefinite delivery contract.
Was contract SPE2DR26F7NKF competed?
The extent of competition for SPE2DR26F7NKF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award